| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000031528 |
| Receipt No. | R000036003 |
| Official scientific title of the study | Effect of 5-aminolevulinic acid phosphate with sodium ferrous citrate on feeling of physical fatigue in healthy subjects -2nd trial |
| Date of disclosure of the study information | 2018/03/02 |
| Last modified on | 2019/03/04 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Effect of 5-aminolevulinic acid phosphate with sodium ferrous citrate on feeling of physical fatigue in healthy subjects -2nd trial | |
| Title of the study (Brief title) | Effect of 5-aminolevulinic acid phosphate with sodium ferrous citrate on feeling of physical fatigue in healthy subjects -2nd trial | |
| Region |
|
|
| Condition | ||
| Condition | Healthy volunteers | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To determine whether 5-aminolevulinic acid phosphate with sodium ferrous citrate improves physical fatigue in healthy subjects. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Change of VAS (Visual Analogue Scale) for overall fatigue from baseline
(Time frame: Baseline, week 0, week 4, and week 8) |
| Key secondary outcomes | 1) Change of VAS for fatigue due to work, work efficiency, and fatigue when one wakes up, from baseline
(Time frame: Baseline, week 0, week 4, and week 8) 2) Change of POMS2 (Profile of Mood States 2nd Edition-Adult)-T scores of Fatigue-Inertia and Vigor-Activity from baseline (Time frame: Baseline, week 0, week 4, and week 8) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | YES |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Subjects receive 3 tablets/day containing a total of 30 mg of 5-aminolevulinic acid phosphate and 34.5 mg of sodium ferrous citrate (3.6 mg as Fe) for 8 weeks. | |
| Interventions/Control_2 | Subjects receive 3 placebo tablets/day containing a total of 34.5 mg of sodium ferrous citrate (3.6 mg as Fe) for 8 weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Healthy with physical fatigue on a day-to-day basis (VAS>=40 mm at baseline)
2) POMS2-T score of Fatigue-Inertia >=50, and POMS2-T score of Vigor-Activity<=60 at baseline |
|||
| Key exclusion criteria | 1) Taking medicines for chronic disease
2) Taking functional food that may affect the trial 3) Participation in any clinical trial within 90 days of the commencement of the trial 4) In pregnancy or nursing a child 5) Judged as ineligible by clinical investigators |
|||
| Target sample size | 70 | |||
| Research contact person | |
| Name of lead principal investigator | Fumiko Higashikawa |
| Organization | Graduate School of Biomedical and Health Sciences, Hiroshima University |
| Division name | Department of Probiotic Science for Preventive Medicine |
| Address | Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, JAPAN |
| TEL | 082-257-1533 |
| fumiko@hiroshima-u.ac.jp | |
| Public contact | |
| Name of contact person | Fumiko Higashikawa |
| Organization | Graduate School of Biomedical and Health Sciences, Hiroshima University |
| Division name | Department of Probiotic Science for Preventive Medicine |
| Address | Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, JAPAN |
| TEL | 082-257-1533 |
| Homepage URL | |
| fumiko@hiroshima-u.ac.jp | |
| Sponsor | |
| Institute | Hiroshima University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | SBI ALApromo Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 広島大学病院(広島県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000036003 |